Suppr超能文献

拓扑异构酶(DNA)I(TOP1)的抑制:DNA损伤修复与抗癌治疗

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.

作者信息

Xu Yang, Her Chengtao

机构信息

School of Molecular Biosciences, College of Veterinary Medicine, Washington State University, Mail Drop 64-7520, Pullman, WA 99164, USA.

出版信息

Biomolecules. 2015 Jul 22;5(3):1652-70. doi: 10.3390/biom5031652.

Abstract

Most chemotherapy regimens contain at least one DNA-damaging agent that preferentially affects the growth of cancer cells. This strategy takes advantage of the differences in cell proliferation between normal and cancer cells. Chemotherapeutic drugs are usually designed to target rapid-dividing cells because sustained proliferation is a common feature of cancer [1,2]. Rapid DNA replication is essential for highly proliferative cells, thus blocking of DNA replication will create numerous mutations and/or chromosome rearrangements-ultimately triggering cell death [3]. Along these lines, DNA topoisomerase inhibitors are of great interest because they help to maintain strand breaks generated by topoisomerases during replication. In this article, we discuss the characteristics of topoisomerase (DNA) I (TOP1) and its inhibitors, as well as the underlying DNA repair pathways and the use of TOP1 inhibitors in cancer therapy.

摘要

大多数化疗方案都包含至少一种优先影响癌细胞生长的DNA损伤剂。该策略利用了正常细胞和癌细胞在细胞增殖方面的差异。化疗药物通常设计用于靶向快速分裂的细胞,因为持续增殖是癌症的一个共同特征[1,2]。快速的DNA复制对于高增殖细胞至关重要,因此阻断DNA复制会产生大量突变和/或染色体重排,最终引发细胞死亡[3]。基于这些,DNA拓扑异构酶抑制剂备受关注,因为它们有助于维持复制过程中由拓扑异构酶产生的链断裂。在本文中,我们讨论了拓扑异构酶(DNA)I(TOP1)及其抑制剂的特性,以及潜在的DNA修复途径和TOP1抑制剂在癌症治疗中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a5/4598769/e2e180db907f/biomolecules-05-01652-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验